We are monitoring the impact of COVID-19 on Europe Anti-neoplastic Agents Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 8048
Share on
Share on

Europe Anti-neoplastic Agents Market Research Report – Segmented By Product Type, End User & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 8048
Pages: 145

The size of the European Anti-neoplastic Agents Market is forecasted to hike at a robust CAGR between 2021 to 2026.

Increasing investment in cancer research by multinational corporations due to rising cancer prevalence is predicted to drive the European market for anti-neoplastic drugs over the forecast period. The anti-neoplastic agent market is expected to develop as cancer incidences increase and the senior population grows. Consumers' lifestyles are changing, which means the danger of cancer is rising. This has piqued the interest of numerous pharmaceutical companies to enter the anti-neoplastic agent industry, increasing in the antineoplastic agent market. Manufacturers of anti-neoplastic medicines have a tremendous opportunity due to several technological advancements in customized medicine. The chemotherapeutic agent sector is likely to lead the market due to simple access to pharmaceuticals. In contrast, the immunotherapeutic agent segment is expected to develop significantly due to the growing acceptability of biological therapy due to fewer side effects.

Furthermore, the market's expected rise is related to rising cancer cases and the desire for cost-effective medicines over the forecasted timeframe. One of the most common reasons for such events is changes in an individual's DNA, resulting in reduced gene activity and, eventually, Cancer. Furthermore, as the number of people afflicted with cancer rises, the Antineoplastic Therapy Market is likely to develop in the next few years as new and improved technologies are discovered. These medications are used in radiotherapies, surgeries, hormone therapies, and other targeted therapies combined with other drugs, which drives market trends. The antineoplastic agents market is also driven by stringent regulations about the safety of drug development procedures and the effectiveness of quality control and quality assurance rules that regulate the pharmaceutical and related industries in several industrialized nations.

Physicians and researchers face a significant challenge in meeting unmet requirements in treating malignant neoplasms as the number of patients grows. Antineoplastic medicines are frequently employed as first-line therapy for cancer treatment and in conjunction with surgery or radiation therapy. However, the varied nature of cancer and the high development cost of anti-neoplastic drugs restrict the market's growth. Anti-neoplastic drugs are costly due to the significant expenses associated with their development. As a result, some customers cannot afford these agents, which is expected to hamper the growth of the antineoplastic agents market in the European region.

This research report on the European Anti-neoplastic Agents market has been segmented and sub-segmented into the following categories.

By Product:

  • Chemotherapeutic Agents
  • Biological Agents   
  • Personalized Medicine  

By End Users:

  • Hospitals 
  • Clinics        
  • Cancer Rehabilitation Centers            
  • Ambulatory Surgical Centers           

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

In the global market for anti-neoplastic agents, Europe is predicted to have the second most significant market share during the forecast period. According to Cancer Research UK, 605 persons per 100,000 were diagnosed with cancer in 2013. The antineoplastic market is predicted to increase rapidly as new cases of neoplasms are reported in the region. The demand for cost-effective medicines to treat neoplasms is projected to drive the Antineoplastic Agents Market in the near future. In addition, the Antineoplastic Therapy Market is being driven by an increase in the flow of funds into research and development by national and international organizations such as the WHO.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merc & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, and AbbVie Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product                        

                                5.1.1 Introduction           

                                5.1.2 Chemotherapeutic agent 

                                5.1.3 Biological agents   

                                5.1.4 Personalied medicine         

                                5.1.5  Y-o-Y Growth Analysis, By Product              

                                5.1.6  Market Attractiveness Analysis, By Product            

                                5.1.7  Market Share Analysis, By Product              

                5.2 End user                      

                                5.2.1 Introduction           

                                5.2.2 Hospitals  

                                5.2.3 Clinics        

                                5.2.4 Cancer rehabilitaion centers            

                                5.2.5 Ambulatory surgical centers            

                                5.2.6 Y-o-Y Growth Analysis, By end user             

                                5.2.7 Market Attractiveness Analysis, By end user           

                                5.2.8 Market Share Analysis, By end user             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By end user

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By end user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By end user

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Hoffmann-La Roche Ltd                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen Inc.                 

                8.3 Bristol-Myers Squibb Company                         

                8.4 Baxter Healthcare Corporation                          

                8.5 Boehringer Ingelheim GmbH                              

                8.6 Aspen Global Inc.                     

                8.7 Bayer AG                     

                8.8 Teva pharmaceutical Industries Ltd.                

                8.9 Johnson & Johnson Pvt. Ltd.                               

                8.10 Accord Healthcare, Inc.                       

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Product Type, by End user along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Europe Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  2. Europe Chemotherapeutic agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Biological agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Personalised medicine Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  6. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Cancer rehabilitation centers Market, By Region, From 2021 to 2026 (USD Billion)
  9. Europe Ambulatory surgical centers Market, By Region, From 2021 to 2026 (USD Billion)
  10. U.K. Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  11. U.K. Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  12. Germany Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  13. Germany Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  14. France Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  15. France Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  16. Italy Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  17. Italy Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)
  18. Spain Anti-neoplastic agents Market, By Product, From 2021 to 2026 (USD Billion)
  19. Spain Anti-neoplastic agents Market, By End user, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample